AgingResearch.NewsJoin free

Everolimus-eluting stent

Intervention

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 4 of 4 findings with company ties
  • Human trial1

Outcomes

1

Target vessel revascularisation

downin humans1

1 study

  1. Everolimus-eluting stent decreases target vessel revascularisation in humans (0.39 [0.24-0.64], p=0.0001).

    “target vessel revascularisation (21 [2%] vs 54 [6%], 0.39 [0.24-0.64], p=0.0001)”

    Human trialundergoing percutaneous coronary intervention12 monthsn = 1,800

    Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

    Lancet (London, England)7 Jan 2010

Associations

3

Myocardial infarction

downin humans1

1 study

  1. Everolimus-eluting stent lowers the risk of myocardial infarction in humans (0.52 [0.33-0.84], p=0.007).

    “myocardial infarction (25 [3%] vs 48 [5%], 0.52 [0.33-0.84], p=0.007)”

    Human trialundergoing percutaneous coronary intervention12 monthsn = 1,800

    Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

    Lancet (London, England)7 Jan 2010

More on Myocardial infarction

Stent thrombosis

downin humans1

1 study

  1. Everolimus-eluting stent lowers the risk of stent thrombosis in humans (0.26 [0.11-0-64], p=0.002).

    “lower rate of stent thrombosis (6 [<1%] vs 23 [3%], 0.26 [0.11-0-64], p=0.002)”

    Human trialundergoing percutaneous coronary intervention12 monthsn = 1,800

    Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

    Lancet (London, England)7 Jan 2010

More on Stent thrombosis

All-cause mortality, myocardial infarction, and target vessel revascularisation

downin humans1

1 study

  1. Everolimus-eluting stent lowers the risk of all-cause mortality, myocardial infarction, and target vessel revascularisation in humans (relative risk 0.69 [95% CI 0.50-0.95], p=0.02).

    “The primary endpoint occurred in 56 (6%) of 897 patients in the everolimus-eluting stent group versus 82 (9%) of 903 in the paclitaxel-eluting stent group (relative risk 0.69 [95% CI 0.50-0.95]”

    Human trialundergoing percutaneous coronary intervention12 monthsn = 1,800

    Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

    Lancet (London, England)7 Jan 2010

Latest

Related